Cyclopentyl Bonded To -coor, -ccoor, Or -cccoor Patents (Class 562/504)
-
Patent number: 6593489Abstract: 3,4-Disubstituted-1-cyclopentene compounds, in substantially enantiopure form, have the relative stereochemistry according to formula (1A) or (1B) including the opposite enantiomers thereof, wherein R1 is either COOX, wherein X is selected from the group consisting of alkyl, H, and a salt-forming cation, or CH2OH, whererin the hydroxy group is optionally protected; R2 is H or a protecting group; R3 is H or alkyl, and R4 is selected from the group consisting of H, alkoxy, alkyl, aryl, and aralkyl; or, in the case of formula (1A), R2 and R4 are linked to form an oxazolidonone ring. These compounds can be used to prepare a series of complementary stereochemcially varied cyclopentane scaffolds.Type: GrantFiled: September 11, 2000Date of Patent: July 15, 2003Assignee: ChirotechTechnology LimitedInventors: Mark Edward Brennan Smith, Nadine Derrien
-
Patent number: 6576786Abstract: The invention relates to a process for preparing substituted cyclopentane derivatives represented by the formula (I) wherein R1, R2, R3, R4, X and Y are as described in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to a process for purifying the compound of formula (Ia) and novel crystalline forms of the compound of formula (Ia).Type: GrantFiled: November 26, 2001Date of Patent: June 10, 2003Assignee: Biocryst Pharmaceuticals Inc.Inventors: Ahmed F. Abdel-Magid, Hans-Ulrich Bichsel, Daniel J. Korey, Gunther G. Laufer, Erja A. Lehto, Sebastiano Mattei, Max Rey, Thomas W. Schultz, Cynthia Maryanoff
-
Publication number: 20030105097Abstract: The invention provides compounds of formula (I) 1Type: ApplicationFiled: May 6, 2002Publication date: June 5, 2003Applicant: Pfizer Inc.Inventors: Andrew Simon, Alan Stobie
-
Publication number: 20030105132Abstract: The invention relates to compounds of formula (I) for treating for example sexual dysfunction, wherein R1 is optionally substituted C1-6alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, hydrogen, C1-6alkoxy, —NR2 R3 or —NR4SO2R5; X is the linkage —(CH2)n— or —(CH2)q—O— (wherein Y is attached to the oxygen); wherein one or more hydrogen atoms in linkage X may be replaced independently by C1-4alkoxy; hydroxy; hydroxy(C1-3alkyl); C3-7cycloalkyl; carbocyclyl; heterocyclyl; or by C1-4alkyl optionally substituted by one or more fluoro or phenyl groups; n is 3, 4, 5, 6 or 7; and q is 2, 3, 4, 5 or 6; and Y is phenyl or pyridyl, each of which may be substituted; or two R8 groups on adjacent carbon atoms together with the interconnecting carbon atoms may form a fused optionally substituted 5- or 6-membered carbocyclic or heterocyclyic ring.Type: ApplicationFiled: March 12, 2002Publication date: June 5, 2003Inventors: Stephen Challenger, Andrew Simon Cook, Adam Thomas Gillmore, Donald Stuart Middleton, David Cameron Pryde, Alan Stobie
-
Patent number: 6562861Abstract: Compounds I-III wherein U is CH, O, or S; Z is mono- or di-substituted carbon; R is (CH2)nCO2H, (CH2)nSO3H, (CH2)nPO3H2, (CH2)nNO2, CH(SCH3)3, esters; R1 is H, hydroxyalkyl, aminoalkyl, alkoxyalkyl; RR1 is O; n is 0-4; R2, R3 is H, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkyl; R4 is (CH2)nOH, (CH2)nNH2, substituted alkyl were prepd. as neuraminidase inhibitors. Thus, (1R,3R,4R,1′S)-(−)-(1′-acetylamino-2 ′-ethyl)butyl-4-(aminoimino)methylaminocyclopentan-1-carboxylic acid was prepd. and tested in vitro as neuraminidase inhibitor (IC50<1.mu.M).Type: GrantFiled: May 25, 2000Date of Patent: May 13, 2003Assignee: BioCryst Pharmaceuticals, Inc.Inventors: Yarlagadda S. Babu, Pooran Chand, John A. Montgomery
-
Publication number: 20030069438Abstract: 1Type: ApplicationFiled: June 6, 2002Publication date: April 10, 2003Inventors: Justin Stephen Bryans, David Clive Blakemore, Sophie Caroline Williams
-
Patent number: 6531485Abstract: This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.Type: GrantFiled: December 16, 1999Date of Patent: March 11, 2003Assignee: Pfizer Inc.Inventors: Kimberly O. Cameron, Paul A. DaSilva-Jardine
-
Patent number: 6531509Abstract: Pharmaceutical compositions containing substantially pure and stable gabapentin are disclosed wherein gabapentin contains an anion of a mineral acid, such as chloride, in amounts greater than 20 ppm.Type: GrantFiled: June 15, 2001Date of Patent: March 11, 2003Assignee: Teva Pharmaceutical Industries Ltd.Inventors: Claude Singer, Gideon Pilarski, Michael Pesachovich, Edward Schwartz
-
Patent number: 6518305Abstract: Disclosed are compounds of the formula: which are useful for inhibiting neuraminidases from disease-causing microorganisms, especially, influenza neuraminidase. Also disclosed are compositions and methods for preventing and treating diseases caused by microorganisms having a neuraminidase, processes for preparing the compounds and synthetic intermediates used in these processes.Type: GrantFiled: October 19, 1999Date of Patent: February 11, 2003Assignee: Abbott LaboratoriesInventors: Clarence J. Maring, Yuanwei Chen, David A. Degoey, Vincent L. Giranda, David J. Grampovnik, Yu Gui Gu, Warren M. Kati, Dale J. Kempf, April Kennedy, Allan C. Krueger, Zhen Lin, Darold L. Madigan, Steven W. Muchmore, Hing L. Sham, Kent D. Stewart, Vincent S. Stoll, Minghua Sun, Gary T. Wang, Sheldon Wang, Ming C. Yeung, Chen Zhao
-
Publication number: 20030008895Abstract: This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.Type: ApplicationFiled: December 16, 1999Publication date: January 9, 2003Inventors: KIMBERLY O CAMERON, PAUL A. DASILVA-JARDINE
-
Patent number: 6503745Abstract: New cyclopentane and cyclopentene compounds are provided along with their use in method for detecting influenza virus.Type: GrantFiled: May 7, 2001Date of Patent: January 7, 2003Assignee: Biocryst Pharmaceuticals, Inc.Inventors: Pooran Chand, Yarlagadda S. Babu, Shanta Bantia
-
Patent number: 6495711Abstract: The invention relates to a process for preparing (−)-(1S,4R) N protected 4-amino-2-cylcopentene-1-carboxylate esters represented by the formula (I) wherein R1 and R2 are as described within the specification.Type: GrantFiled: December 18, 2001Date of Patent: December 17, 2002Assignee: BioCryst Pharmaceuticals Inc.Inventors: Max Rey, Gregor Welti, Cynthia Maryanoff
-
Publication number: 20020133009Abstract: The present invention relates to a method for opening potassium channels in mammalian cells by administering to a mammal effective amounts of potassium channel-opening keto compounds as described herein.Type: ApplicationFiled: March 4, 2002Publication date: September 19, 2002Inventors: George N. Lambrou, Anna Ottlecz, Christine Percicot, Michael Wiederholt
-
Publication number: 20020086234Abstract: The present invention provides a novel ammonium salt of an organic acid. When the salt is used as a base additive for a chemically amplified resist, the environmental stability of the resist can be enhanced, and the T-top phenomenon can be effectively prevented. In addition, the line width change caused by acid diffusion can be prevented, and the E0 value of the resist can be decreased.Type: ApplicationFiled: March 9, 2001Publication date: July 4, 2002Inventors: Sheng-Yueh Chang, Jiam-Hong Chen, Ting-Chun Liu, Tzu-Yu Lin, Wen-Yuang Tsai
-
Patent number: 6410594Abstract: Compounds represented by formula (I), and pharmaceutically acceptacle salts thereof; and their method of preparation are provided. Compounds of the above formula are influenza virus neuraminidase inhibitors and can be used in treating patients infected with influenza virus.Type: GrantFiled: June 9, 1999Date of Patent: June 25, 2002Assignee: Biocryst Pharmaceuticals, Inc.Inventors: Yarlagadda S. Babu, Pooran Chand, John A. Montgomery
-
Patent number: 6395930Abstract: A method for enhancing the purity of a desired compound comprising: Step (a) treating a crude reaction product which contains at least one desired compound, unreacted starting materials and/or byproducts with at least one bifunctional quenching agent that is capable of selective covalent reaction with unwanted byproducts, or excess reagents; Step (b) allowing the quenching agent to covalently react with unreacted starting materials and/or byproducts to afford a derivatized compound of the quenching agent: and Step (c) isolating the desired compound is described as well as novel quenching agents and methods for their use in the rapid purification of synthetic intermediates and products in synthesis, combinatorial chemistry, and automated organic synthesis.Type: GrantFiled: May 25, 2000Date of Patent: May 28, 2002Assignee: Warner LambertInventor: Sham Nikam
-
Patent number: 6329429Abstract: GABA analogs such as gabapentin and pregabalin are useful to prevent and treat inflammatory diseases.Type: GrantFiled: October 25, 1999Date of Patent: December 11, 2001Assignee: Warner-Lambert CompanyInventors: Denis Schrier, Charles Price Taylor, Jr., Karin Nanette Westlund High
-
Patent number: 6316659Abstract: A process for preparing cyclopentanone and cyclopentene-1-carboxylic acid or an ester thereof of the formula I where R is hydrogen or an aliphatic radical having 1-6 carbon atoms or a cycloaliphatic, araliphatic or aromatic radical having 6-12 carbon atoms comprises heating a compound of the formula II X—(CH2)4—COOR II where X is formyl or hydroxymethyl and R is defined as above, and/or a compound which is converted into a compound of the formula II by reaction with water or alcohols ROH under the reaction conditions to from 200 to 450° C. in the gas or liquid phase in the presence of a heterogeneous oxidic catalyst.Type: GrantFiled: March 7, 2000Date of Patent: November 13, 2001Assignee: BASF AktiengesellschaftInventors: Rolf Fischer, Shelue Liang, Rolf Pinkos, Frank Stein
-
Patent number: 6310084Abstract: The present invention relates to therapeutically active hydroxamic acid, N-formyl-N-hydroxyamino and carboxylic acid derivatives, their preparation, and pharmaceutical compositions containing them. These compounds are useful in the inhibition of metalloproteases, such as stromelysin, gelatinase, matrilysin, and collagenase. These compounds are useful in the treatment of mammals having disease-states alleviated by the inhibition of such matrix metalloproteases.Type: GrantFiled: February 11, 2000Date of Patent: October 30, 2001Assignee: British Biotech Pharmaceuticals LimitedInventors: Raymond Paul Beckett, Fionna Mitchell Martin, Richard Simon Todd
-
Patent number: 6124476Abstract: The present invention discloses new organic compounds (e.g., ligands), their metal complexes and compositions using those compounds. The invention also relates to the field of catalysis. In particular, this invention relates to new compounds which when combined with suitable metals or metal precursor compounds provide useful catalysts for various bond-forming reactions, including Suzuki cross-coupling reactions. The invention also relates to performing Suzuki cross coupling reactions with unreactive aryl-chlorides.Type: GrantFiled: February 18, 1999Date of Patent: September 26, 2000Assignee: Symyx Technologies, Inc.Inventors: Anil Guram, Xiaohong Bei, Timothy S. Powers, Bernd Jandeleit, Thomas Crevier
-
Patent number: 6054482Abstract: The present invention concerns cyclic amino acids of formula ##STR1## substantially free from the lactam ##STR2## wherein n is an integer of from 4 to 6, a process for the preparation thereof, compositions containing the compounds and methods of using them.Type: GrantFiled: January 25, 1995Date of Patent: April 25, 2000Assignee: Godecke AktiengesellschaftInventors: Helmut Augart, Uwe Gebhardt, Wolfgang Herrmann
-
Patent number: 6025518Abstract: A substituted cyclopentene derivative of formula (V): whereinX.sup.1 is (.alpha.-OZ.sup.a, .beta.-H) or (.alpha.-H, .beta.-OZ.sup.a), X.sup.3 is (.alpha.-OZ.sup.d, .beta.-H), (.alpha.-H, .beta.-OZ.sup.d), or oxygen atom, each of Z.sup.a and Z.sup.d, which may be the same or different, is a hydrogen atom or a protective radical for a hydroxyl radical;U is a radical selected from the group consisting of CR.sup.1 HCH.sub.2, CR.sup.1 .dbd.CH and C.tbd.C,whereinR.sup.1 is a hydrogen atom, halogen atom, substituted silyl radical represented by SiR.sup.9 R.sup.10 R.sup.11 or substituted stannyl radical represented by SnR.sup.14 R.sup.15 R .sup.16,m is an integer of 0 to 6;X.sup.2 is CH.dbd.CH or C.tbd.C,p is an integer of 0 or 1, each of n and q is an integer of 0 to 5; andZ.sup.1 is a hydrogen atom, COOR.sup.y, CN, OH, OCOR.sup.2, CONR.sup.b R.sup.c or NR.sup.d R.sup.e.Type: GrantFiled: September 8, 1998Date of Patent: February 15, 2000Assignees: Nissan Chemical Industries, Ltd., Fumie SATOInventor: Fumie Sato
-
Patent number: 6020370Abstract: Bridged cyclic amino acids of formula ##STR1## are disclosed and are useful as agents in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain and neuropathological disorders. Processes for the preparation and intermediates useful in the preparation are also disclosed.Type: GrantFiled: May 19, 1998Date of Patent: February 1, 2000Assignee: Warner-Lambert CompanyInventors: David Christopher Horwell, Justin S. Bryans, Clare O. Kneen, Andrew I. Morrell, Giles S. Ratcliffe
-
Patent number: 5990165Abstract: A pharmaceutical compound of the formula: ##STR1## in which n is 1 or 2, R.sup.1 is --CO.sub.2 H, R.sup.2 is hydrogen or C.sub.1-4 alkyl andR.sup.3 is hydrogen, C.sub.1-10 alkyl, C.sub.2-10 alkenyl, optionally substituted phenyl, optionally substituted phenyl-C.sub.1-4 alkyl, optionally substituted phenyl C.sub.2-10 alkenyl,(optionally substituted phenyl).sub.2 -C.sub.1-4 alkyl, optionally substituted C.sub.3-7 cycloalkyl, optionally substituted C.sub.3-7 cycloalkyl-C.sub.1-4 alkyl or optionally substituted C.sub.3-7 cycloalkyl-C.sub.2-10 alkenyl, orR.sup.2 and R.sup.3, together with the carbon atom to which they are attached, form an optionally substituted C.sub.4-7 cycloalkyl group;or a salt or ester thereof other than the compounds .gamma.-propylidene-L-glutamic acid, .gamma.-ethylidene-L-glutamic acid and .gamma.-methylidene-L-glutamic acid.Type: GrantFiled: March 24, 1998Date of Patent: November 23, 1999Assignee: Lilly, S.A.Inventors: Concepcion Pedregal Tercero, Almudena Rubio Esteban
-
Patent number: 5959141Abstract: The invention is directed to optically active 1-amino-hydroxycycloalkanecarboxylic acid compounds represented by the formula: ##STR1## wherein n is 0, 1, 2, 3, or 4; methods of their synthesis; and their use as compounds to fix the confirmation of a peptide or protein molecule when introduced into the peptide or protein in the place of a normal amino acid.Type: GrantFiled: March 10, 1998Date of Patent: September 28, 1999Assignee: Suntory LimitedInventors: Manabu Horikawa, Yasufumi Ohfune
-
Patent number: 5948935Abstract: Disclosed herein is a process for preparing (S)-.alpha.-amino-1-carboxycyclopentaneacetic acid which is a useful intermediate for preparing peptidomimetic inhibitors of herpes viral ribonucleotide reductase. The process comprises the preparation of the key intermediate ##STR1## and its subsequent conversion to the desired product.Type: GrantFiled: January 23, 1998Date of Patent: September 7, 1999Assignee: Boehringer Ingelheim (Canada) Ltd.Inventors: Jean-Marie Ferland, Ingrid Guse, Eric Malenfant
-
Patent number: 5935988Abstract: The present invention relates to mixtures of .alpha.-amino acids and/or derivatives thereof and cyclopentane-.beta.-amino acids and/or derivatives thereof, dipeptides of the abovementioned .alpha.-amino acids and cyclopentane-.beta.-amino acids and mixtures of the abovementioned mixtures and dipeptides which have an improved tolerability in warm-blooded animals compared with the pure cyclopentane-.beta.-amino acids.Type: GrantFiled: July 12, 1996Date of Patent: August 10, 1999Assignee: Bayer AktiengesellschaftInventors: Michael Matzke, Hans-Christian Militzer, Joachim Mittendorf, Franz Kunisch, Axel Schmidt, Wolfgang Schonfeld, Karl Ziegelbauer
-
Patent number: 5932595Abstract: The present invention relates to compounds of Formula I: ##STR1## that are matrix metalloprotease inhibitors, pharmaceutical compositions containing them, methods for their use and methods of preparing these compounds.Type: GrantFiled: December 18, 1996Date of Patent: August 3, 1999Assignees: Syntex (U.S.A.) Inc., Agouron Pharmaceuticals, Inc.Inventors: Steven Lee Bender, Chris Allen Broka, Jeffrey Allen Campbell, Arlindo Lucas Castelhano, Lawrence Emerson Fisher, Robert Than Hendricks, Keshab Sarma
-
Patent number: 5877343Abstract: The process according to the invention for the preparation of enantiomerically pure cyclopentane-.beta.-amino acids of the general formula (I) ##STR1## in which A and D have the meanings given in the description, is characterized in that meso-dicarboxylic acid anhydrides are first converted by asymmetric alcoholysis with allyl alcohols and in the presence of a chiral amine base present in enantiomerically pure form, in inert solvents, via the intermediate enantiomerically pure salt stage, into the enantiomerically pure dicarboxylic acid monoesters, in a further step these dicarboxylic acid monoesters are intermediately converted, in the sense of a Curtius rearrangement by reaction with azides, into the corresponding acid azides, and are subsequently converted into the corresponding rearranged isocyanates and the isocyanates are then reacted with allyl alcohols to give the compounds of the general formula (VII), and finally the cyclopentane-.beta.Type: GrantFiled: April 25, 1997Date of Patent: March 2, 1999Assignee: Bayer AktiengesellschaftInventor: Joachim Mittendorf
-
Patent number: 5817776Abstract: The invention provides novel amino acid compounds of use in detecting and evaluating brain and body tumors. These compounds combine the advantageous properties of 1-amino-cycloalkyl-1-carboxylic acids, namely, their rapid uptake and prolonged retention in tumors with the properties of halogen substituents, including certain useful halogen isotopes including fluorine-18, iodine-123, iodine-125, iodine-131, bromine-75, bromine-76, bromine-77 and bromine-82. In one aspect, the invention features amino acid compounds that have a high specificity for target sites when administered to a subject in vivo. Preferred amino acid compounds show a target to non-target ratio of at least 5:1, are stable in vivo and substantially localized to target within 1 hour after administration. An especially preferred amino acid compound is ?.sup.18 F!-1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC). In another aspect, the invention features pharmaceutical compositions comprised of an .alpha.Type: GrantFiled: November 8, 1996Date of Patent: October 6, 1998Assignee: Emory UniversityInventors: Mark M. Goodman, Timothy Shoup
-
Patent number: 5808146Abstract: The invention provides novel amino acid compounds of use in detecting and evaluating brain and body tumors. These compounds combine the advantageous properties of 1-amino-cycloalkyl-1-carboxylic acids, namely, their rapid uptake and prolonged retention in tumors with the properties of halogen substituents, including certain useful halogen isotopes including fluorine-18, iodine-123, iodine-125, iodine-131, bromine-75, bromine-76, bromine-77 and bromine-82.In one aspect, the invention features amino acid compounds that have a high specificity for target sites when administered to a subject in vivo. Preferred amino acid compounds show a target to non-target ratio of at least 5:1, are stable in vivo and substantially localized to target within 1 hour after administration. An especially preferred amino acid compound is ?.sup.18 F!-1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC).In another aspect, the invention features pharmaceutical compositions comprised of an .alpha.Type: GrantFiled: November 9, 1995Date of Patent: September 15, 1998Assignee: Emory UniversityInventors: Mark M. Goodman, Timothy Shoup
-
Patent number: 5808147Abstract: The present invention relates to certain purine nucleoside analogues containing a carbocyclic ring in place of the sugar residue, salts, esters and pharmaceutically acceptable derivatives thereof, processes for their preparation, pharmaceutical formulations containing them and to the use of such compounds in therapy, particularly the treatment or prophylaxis of certain viral infections.Type: GrantFiled: November 7, 1997Date of Patent: September 15, 1998Assignee: Glaxo Wellcome Inc.Inventors: Susan Mary Daluge, Douglas Alan Livingston
-
Patent number: 5739160Abstract: New Cyclopentane- or cyclopentene-beta-aminoacid derivatives and their isomers, acid additional salts and metal salt complexes have strong antimicrobial and broad-spectrum antimycotic acitivity. As antimycotics they are especially active against dermatophyte, and biphasic fungi. The new compounds are also low toxicity antibacterial agents, effective against Gram positive bacteria, including antibiotic-resistant strains. The new Cyclopentane- or cyclopentene-beta-aminoacid derivatives are useful in human or veterinary medicine for combating dermatomycosis or systemic mycosis or local or systemic bacterial infections. In addition, the new compounds can also be used as preservatives, especially for water, foods, or organic materials such as polymers, lubricants, paints, fibers, leather, paper or wood.Type: GrantFiled: September 19, 1994Date of Patent: April 14, 1998Assignee: Bayer AktiengesellschaftInventors: Joachim Mittendorf, Franz Kunisch, Michael Matzke, Hans-Christian Militzer, Rainer Endermann, Karl Georg Metzger, Klaus-Dieter Bremm, Manfred Plempel
-
Patent number: 5728866Abstract: A method for preparing 3-oxo-2-pentyl-1-cyclopentaneacetic acid or methyl 3-oxo-2-pentyl-1-cyclopentaneacetate, essentially in the form of the (+)-(1R)-cis isomer thereof. The method includes the steps of(a) catalytically hydrogenating a compound of the formula (I), ##STR1## wherein M is a hydrogen atom, an alkali metal or alkaline earth metal atom, or a group NR.sub.4, where R is a hydrogen or a lower alkyl radical, in a suitable solvent and in the presence of a catalyst consisting of an Ru(II) complex comprising chiral ligands that contain a 2,2'-bis(diphenylphosphino)-1,1'-dinaphthyl (BINAP) radical or a 1,2-bis(2,5-dialkylphospholano)benzyl (DuPHOS) radical, wherein the alkyl is a C.sub.2 or C.sub.3 radical, to give a compound of formula (II), ##STR2## wherein M has the meaning given above, essentially in the form of the (+)-(1R)-cis isomer thereof;(b) if required, acidifying, in a per se known manner, the compound of formula (II), wherein M is an alkali metal or alkaline earth metal atom, or a group N.Type: GrantFiled: February 7, 1996Date of Patent: March 17, 1998Assignee: Firmenich SAInventors: Valentin Rautenstrauch, Jean-Jacques Riedhauser
-
Patent number: 5631291Abstract: The invention relates to cyclopentane- and -pentene-.beta.-amino acids, processes for their preparation and their use as medicaments.Type: GrantFiled: November 9, 1994Date of Patent: May 20, 1997Assignee: Bayer AktiengesellschaftInventors: Joachim Mittendorf, Franz Kunisch, Michael Matzke, Hans-Christian Militzer, Rainer Endermann, Karl G. Metzger, Klaus-Dieter Bremm, Manfred Plempel
-
Patent number: 5618959Abstract: A process for synthesizing prostaglandin E.sub.1, E.sub.2 and derivatives thereof is provided. The process is a "one-pot" method in which 2-furyllithium, copper cyanide, a lower alkyllithium reagent and either an (E)-alkenylstannane or a halogenide are combined with cyclopentenone (II) ##STR1## in which A, R.sup.6 and R.sup.7 are as defined herein. The reaction gives rise to the desired prostaglandin product in yields of 80% or higher.Type: GrantFiled: March 10, 1995Date of Patent: April 8, 1997Assignee: Vivus IncorporatedInventors: Miroslav Trampota, Bohumil Zak
-
Patent number: 5591893Abstract: The invention relates to a process for the preparation of polycarboxylic acids and derivatives thereof, the polycarboxylic acids prepared containing at least three carboxyl groups, comprising the steps(A) introducing one or more organic compounds, which contain nonaromatic carbon-carbon (C--C) double bonds, into water,(B) ozonolysis of the organic compounds in water by passing in an ozone-containing carrier gas,(C) addition of an aqueous hydrogen peroxide solution, to oxidatively work up the ozonolysis products produced in step (B), which comprises, in step (A), introducing the organic compound(s) into water having a pH of 7 or less than 7 and, in step (C), adding hydrogen peroxide in water without adding an organic solvent.Type: GrantFiled: October 27, 1993Date of Patent: January 7, 1997Assignee: Hoechst AGInventors: J urgen Kulpe, Heinz Strutz
-
Patent number: 5545665Abstract: The invention relates to 7-[5-hydroxy-2-(hydroxyhydrocarbyl or heteroatom-substituted hydroxy hydrocarbyl)-3-hydroxycyclopentyl(enyl)] heptanoic or heptenoic acids and derivatives of said acids, wherein one or more of said hydroxy groups are replaced by an ether group. The compounds of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma.Type: GrantFiled: December 28, 1993Date of Patent: August 13, 1996Assignee: AllerganInventor: Robert M. Burk
-
Patent number: 5532408Abstract: Provided are .alpha.-chain-modified isocarbacyclins of which the .alpha.-chain is modified with a phenylene group, a cycloalkylene group or a thiophendiyl group, and these .alpha.-chain-modified isocarbacyclins show the activity for inhibiting the DNA synthesis of human smooth muscle cell and are expected to be capable of inhibiting the hypertrophy of a blood vessel.Type: GrantFiled: April 5, 1995Date of Patent: July 2, 1996Assignee: Teijin LimitedInventors: Masahiro Koga, Toshio Tanaka, Takao Fujii, Tsukio Masegi
-
Patent number: 5506244Abstract: Disclosed are the compounds of formula I ##STR1## wherein R represents hydrogen, lower alkyl, carbocyclic or heterocyclic aryl-lower alkyl or cycloalkyl-lower alkyl; R.sub.1 represents hydrogen, lower alkyl, cycloalkyl, carbocyclic aryl or heterocyclic aryl, or biaryl; R.sub.3 represents hydrogen or acyl; R.sub.4 represents hydrogen, lower alkyl, carbocyclic or heterocyclic aryl, carbocyclic or heterocyclic aryl-lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, biaryl or biaryl-lower alkyl; R.sub.5 represents hydrogen or lower alkyl; or R.sub.4 and R.sub.Type: GrantFiled: June 22, 1994Date of Patent: April 9, 1996Assignee: Ciba-Geigy CorporationInventor: Cynthia A. Fink
-
Patent number: 5488136Abstract: Racemates are obtained from non-racemic 3-oxocyclopentane or 3-oxocyclohexane carboxylic acids or their esters by esterification and ketalization of the non-racemic acid with orthoformic acid ester in an alocohol, racemization and hydrolysis of the product obtained with an alcoholate and isolation of the racemate.Type: GrantFiled: April 16, 1993Date of Patent: January 30, 1996Assignee: Boehringer Ingelheim KGInventor: Rainer Sobotta
-
Patent number: 5455234Abstract: Mammalian hair growth is reduced by applying to the skin an inhibitor of a cysteine synthetic pathway enzyme.Type: GrantFiled: March 16, 1994Date of Patent: October 3, 1995Inventors: Gurpreet S. Ahluwalia, Douglas Shander
-
Patent number: 5436343Abstract: Compounds of formula (I): ##STR1## in which: R.sub.1 and R.sub.2, which may be identical or different, represent a linear or branched (C.sub.1 C.sub.6) alkyl radical, a substituted or unsubstituted phenyl radical, a pyridyl radical or a thienyl radical, or, with the carbon atom to which they are attached, a substituted or unsubstituted (C.sub.4 -C.sub.7) cycloalkyl ring,R.sub.3 representsa substituted or unsubstituted phenylsulfonyl radical,a linear or branched (C.sub.1 -C.sub.6) alkyl radical,an alkylaminocarbonyl radical,or a linear or branched (C.sub.1 -C.sub.6) acyl radical,R.sub.4 represents any one of the radicals:--CH.dbd.CH--(CH.sub.2).sub.p --CO.sub.2 H or --CH.sub.2 --CH.sub.2 --(CH.sub.2)p--CO.sub.2 Hin which p is equal to 0, 1, 2 or 3, n and m, which may be identical or different, represent 0, 1 or 2,their isomers, enantiomers, diastereoisomers and epimers as well as their addition salts with a pharmaceutically acceptable acid or base.Type: GrantFiled: May 14, 1993Date of Patent: July 25, 1995Assignee: Adir et CompagnieInventors: Gilbert Lavielle, Patrick Hautefaye, Michel Laubie, Tony Verbeuren
-
Patent number: 5393924Abstract: Acylamides or amine acylate salts of arylalkanolamines are prepared by reacting an arylisonitrosoalkanone with hydrogen and a carboxylic acid, carboxylic acid anhydride or carboxylic acid ester or mixture thereof in the presence of a transition metal catalyst; optionally the product is converted to the corresponding arylalkanolamine hydrochloride salt by reaction of the acylamide or amine acylate salt of the arylalkanolamine with hydrogen chloride in a C.sub.1 -C.sub.3 alkyl alcohol.Type: GrantFiled: April 29, 1994Date of Patent: February 28, 1995Assignee: Hoechst Celanese CorporationInventors: Ahmed M. Tafesh, Olan S. Fruchey, Charles B. Hilton
-
Patent number: 5335769Abstract: A freeze-drying process which reduces loss of the freeze-dried product comprising adding a liquid solution comprising a solid product dissolved in a solvent to a glass container having its inside surface coated with a silicone material; subjecting the container with the liquid solution therein to acceptable operable freeze-drying conditions to remove the solvent and leave the solid product in the container in the form of a dense compact coherent solid; and sealing the container to maintain the solid product stable over a useful storage shelf life.An article of manufacture comprising a sealed glass container having its inside surface coated with a silicone material and containing an in situ freeze-dried dense compact coherent solid product.Type: GrantFiled: November 5, 1992Date of Patent: August 9, 1994Assignee: Schwartz Pharma AGInventors: Karin Klokkers-Bethke, Wilfried Fischer
-
Patent number: 5319135Abstract: An improved process for the preparation of cyclic amino acids by a novel synthesis is described where a dinitrile derivative is converted in two steps to the desired products, as well as valuable intermediates used in the process.Type: GrantFiled: June 4, 1993Date of Patent: June 7, 1994Assignee: Warner-Lambert CompanyInventors: Rex A. Jennings, Don R. Johnson, Ronald E. Seamans, James R. Zeller
-
Patent number: 5294616Abstract: A series of non-peptide derivatives that are antagonists of the fibrinogen IIb/IIIa receptor and thus are platelet aggregation compounds useful in the prevention and treatment of diseases caused by thrombus formation.Type: GrantFiled: March 25, 1992Date of Patent: March 15, 1994Assignee: Merck & Co., Inc.Inventors: Mark E. Duggan, Melissa S. Egbertson, Wasyl Halczenko, George D. Hartman, Laura M. Turchi, William L. Laswell
-
Patent number: 5191115Abstract: To produce a carboxylic acid R.sup.1 --COOH, in which R.sup.1 is a tertiary branched alkyl residue or a cycloalkyl residue with one or more rings, which may be attached, and possibly substituted by at least one alkyl residue, the alpha carbon atom of the carbonyl group being a tertiary carbon atom, a branched or cyclic alkane R.sup.1 H, in which R.sup.1 is a branched alkyl residue or a cycloalkyl residue with one or more rings, which may be attached, and possibly substituted by at least one alkyl residue, the alpha carbon atom of the hydrogen atom being a tertiary carbon atom or a secondary carbon atom capable of being rearranged during reaction to a tertiary atom, is reacted in the presence of an acid catalyst with a formiate H(CO)O(CR.sup.2 R.sup.3 R.sup.4), in which R.sup.2, R.sup.3 and R.sup.4 denote hydrogen or alkyl, under the three following conditions: that R.sup.2, R.sup.3 and R.sup.Type: GrantFiled: February 5, 1991Date of Patent: March 2, 1993Assignee: AtochemInventors: Veronique Lazzeri, Roger Gallo, Rachid Jalal
-
Patent number: 5164412Abstract: A Derivative of 5-hetero-6-oxo-PGE A derivative of 5-hetero-6-oxo-PGE of the formula: ##STR1## wherein R.sup.1 is (1) a group of the formula: COOR11(2) hydroxymethylcarbonyl,(3) hydroxymethyl or(4) a group of the formula:CO--AAwherein AA is an amino acid-residue,Z is oxygen, sulfur or a group of the formula: NR21 wherein R21 is hydrogen or alkyl of C1--4;R2 is a single-bond or alkylene of C1--4;R3 isi) alkyl of C1-7,ii) cycloalkyl of C4-7 or cycloalkyl of C4-7 substituted by alkyl of C1-7,iii) phenyl, phenoxy, phenyl or phenoxy substituted by one group selected from alkyl of C1-4, halogen and trihalomethyl, is single-bond or a double bond.Possess PG-like activity, especially cytoprotection, and therefore are useful for treatment for and/or prevention of cytodamage.Type: GrantFiled: April 8, 1991Date of Patent: November 17, 1992Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Yoshitaka Konishi, Masanori Kawamura
-
Patent number: 5116869Abstract: 2-Substituted-2-cyclopentenones represented by the formula (I): ##STR1## wherein A is a hydroxyl group or ##STR2## and B is a hydrogen atom or A and B are bonded together to form one bonding arm;R.sup.1 represents a substituted or unsubstituted hydrocarbon group having 1 to 10 carbon atoms;R.sup.2 represents a substituted or unsubstituted aliphatic hydrocarbon group having 1 to 10 carbon atoms;R.sup.3 represents a substituted or unsubstituted aliphatic hydrocarbon group having 1 to 10 carbon atoms; wherein,when R.sup.3 is a single bond bonded to the cyclopentene skeleton, X represents a hydrogen atom, a hydroxyl group or a protected hydroxyl group; andwhen R.sup.3 is a double bond bonded to the pentene skeleton, X represents a bonding arm constituting a part of said double bond; andm and n independently represent 0, 1 or 2.Type: GrantFiled: September 3, 1991Date of Patent: May 26, 1992Assignee: Teijin LimitedInventors: Satoshi Sugiura, Atsuo Hazato, Toru Minoshima, Yoshinori Kato, Yasuko Koshihara, Seizi Kurozumi